

## **AIMS AND SCOPE**

The Iranian Biomedical Journal (IBJ) takes pride in its leadership comprised of a wide range of disciplines in the field of Biomedicine. IBJ is proud to offer a receptive medium for rapid, peer-reviewed publication for original articles (full length and short communications), as well as expert scientific reviews. It strives to maintain a dynamic growth of the quality of its publications, and welcomes submissions in the following fields:

1. Molecular Microbiology
2. Molecular Genetics & Genomics
3. Molecular Immunology and Vaccines
4. Cancer Biology
5. Pharmaceutical Biotechnology
6. Medical Biotechnology
7. Enzymology and Protein Chemistry
8. Tissue Engineering and Cell Biology
9. And related fields

## **OPEN ACCESS**

IBJ is an open access journal. In other words, all contents are publicly available free of charge. Since January 2020, all articles published in IBJ are under a Creative Commons Attribution-Non Derivatives 4.0 International License (CC BY-ND 4.0), which allows users to read, download, copy, distribute, and print.

## **COPYRIGHT**

All authors must sign the '[Copyright Transfer Agreement Form](#)' before the article can be processed. This transfer agreement enables IBJ to protect the copyrighted material and provides IBJ with the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. It also includes the right to adapt the article for use in conjunction with computer systems and programs, including reproduction or publication in machine-readable form and incorporation in retrieval systems. Readers and authors are responsible for obtaining permission from the copyright holder (IBJ) to reproduce any and all figures covered by copyright.

## **Manuscript Preparation**

Article types accepted by IBJ are as follows: editorials, case reports, letter to the editor, original research (full length and short communication), and descriptive or systematic review articles. Manuscripts should be prepared in accordance with the "[Uniform Requirements for Manuscripts Submission to Biomedical Journals](#)" proclaimed by the [International Committee of Medical Journal \(ICMJ\)](#)".

### ***Language***

Manuscripts should be in American English. The past tense should be used throughout the text, in describing the results. The present tense, however, must be used when referring to previously published materials. Authors who are unsure of the correct English usage should have their manuscript checked by those proficient in the language; manuscripts that are deficient in this respect will be returned to the authors for language polishing, prior to scientific review of the submitted manuscript.

Article type	Max word count (including references)	No. of references	Total no. of tables and figures	Format
Review Article/Systematic Review	9000	150	6	<a href="#">Link</a>
Biography Papers	6000	100	5	<a href="#">Link</a>
Full Length/Original Article	5000	50	8	<a href="#">Link</a>
Perspective	4500	80	4	<a href="#">Link</a>
Mini Review/Meta-Analysis	4500	70	4	<a href="#">Link</a>
Short Communication	3500	25	4	<a href="#">Link</a>
Brief report	2500	25	3	<a href="#">Link</a>
Case report	800	20	4	<a href="#">Link</a>
Commentaries	800	10	1	<a href="#">Link</a>
Letter to the Editor	800	10	2	<a href="#">Link</a>

## GENERAL ARRANGEMENT OF PAPERS

### *Title*

The title must be concise and informative.

### *Authors' name and affiliation*

The title should be followed by the authors' full (first, middle, and last) names and their affiliations, annotated by Arabic numbers (1, 2, 3, ..), in superscript format, next to the authors' names. The authors' ORCID ID should also be included, as well. The name and full postal address, telephone/fax, and E-mail address of the corresponding author should be provided in the footnote.

### *Running title*

A running title of no more than 50 characters (including spaces) should be provided.

### *Abbreviations*

A list of abbreviations should be defined for non-standard abbreviations used three or more times, including those used in the Figures and Tables. [The listed standard abbreviations](#) provided by the Journal, do not need to be spelled out.

### *Abstract*

The abstract should follow the title, as the second page, without authors' names. Inclusion of references must be avoided in the abstract.

### *Keywords*

Three to five keywords should be included at the foot of the abstract for indexing purposes. All keywords should be chosen from [the Medical Subject Headings \(MeSH\)](#) terms, labeled as "MeSH Headings" not "Entry Term".

### *Introduction*

This section should contain a description of the problem under investigation and a brief survey of the existing literature on the subject, ending with the purpose of the study.

### *Materials and methods*

Sufficient details must be provided to allow for the complete reproduction of the work. Complete and accurate names of materials, including chemical and organisms, should be specified followed by the suppliers' information, including name of manufacturer, city, and the country (in parenthesis). [International System of Units \(SI\)](#) and internationally accepted symbols must be used in the manuscript, particularly this section.

## ***Results***

This section should concisely describe the details of the investigation and its outcomes. Data should not be replicated in the text, tables or figures. This section should not be mixed with Discussion.

## ***Discussion***

This section should relate the results to the previous pertinent studies and provide potential interpretations and recommendations. This section should not be mixed with Results.

## ***Conclusion***

This section should state the final result and recommendation that the author(s) has (have) reached. Such results and recommendations should be derived from the researcher's own study and the results of other studies should not be stated in this section.

## ***Acknowledgments***

This section must include expression of gratitude towards contributors who are not included in the authors' list. Authors should disclose in the acknowledgement whether they have used artificial intelligence (AI)-assisted technologies (such as ChatGPT, Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work).

## ***References***

References should be numbered sequentially in the order of their citation in the text. The list of references should appear at the end of the manuscript and follow the order of their citation in the text. For manual preparation of references, authors should follow [Vancouver style](#). In order to use Endnote software, please apply Thomson Reuters reference [output style for Vancouver](#).

## ***Tables and figures***

Tables and Figures should be numbered (1, 2, 3, ...) in the order they appear in the text. Tables and Figures, together with their legends, must be provided at the end of the manuscript in separate pages. The style of Tables should be as simple as possible, with a left-to-right text direction. Also, Figures should be of high quality ( $\geq 300$  dpi), and the size intended for publication should not exceed  $9 \times 12$  cm. All Figures should preferably be in the form of JPG (.jpg). However, other formats, including encapsulated postscript (.eps), Power Point (.ppt), Photoshop (.psd), TIF (.tiff), PNG (png), are also acceptable. In case the figures are not original, authors should mention the original source of the Figures, plus permission from the copyright holder.

## ***Illustrations***

Please note that for every illustration used in the manuscripts, IBJ mandates declaration of ownership. In other words, they are either created by the authors or used with "permission" of the copyright owner, which should be noted accordingly.

## **ETHICAL CONCERNS**

### ***Conflict of interest***

Secondary (e.g. personal, financial, commercial, political, and academic) associations that may influence judgements on a primary decision or what is published can be perceived as conflict of interest. All authors and members of IBJ, including the Editorial Board, should disclose any conflict of interest upon submission. External peer reviewers should also disclose any potential conflicts of interest that could bias their opinions of the manuscript, and should thus disqualify themselves from reviewing such manuscripts. In addition, the reviewers should not use knowledge of the work, before its publication, to further their own interests. In case of any doubt about conflicts of interest, please contact the IBJ Office at [iraniabiomedicalj@gmail.com](mailto:iraniabiomedicalj@gmail.com).

### ***Funding/support***

All sources of grant and other forms of support, including funds received from the contributors, institutions and commercial sources should be provided in the "funding/support section" of the manuscript.

### ***Human and animal subjects***

Authors must provide the ethical approval information in the “Ethical Statement” Section of the manuscript. Animal and human experimental studies must follow the relevant international and national guidelines and regulations, where the research is carried out. Providing appropriate approval of the institutional ethics committee and the pertinent “ethical code” is essential for all submissions including information regarding humans (and/or their medical records) and animals. Human experimental studies should have been conducted in conformity with the Declaration of Helsinki provided by the World Medical Association. Experiments on humans must be performed provisional to obtaining signed written informed consents from the subject or their guardians. The completed consent forms should be stored by authors or their respective institutions, in line with institutional policies. Consent forms should be available upon request from the editor or editorial office, during the review process or post publication. *IBJ* reserves the right to reject submission, if the required documents are not available.

### ***Data availability***

Authors are required to make their “minimal data set” (underlying the findings described and used to reach the conclusions of the manuscript) available to any qualified researchers. The data should be findable, accessible, interpretable, and reusable by interested researchers. In case of any legal, ethical, or privacy restrictions, authors should clearly report these limitations in the “Data Availability Section” of the manuscript. In this section, all necessary information needed to request access to the datasets should be included.

### ***Authorship***

- ***Author contributions:*** The authors’ contributions statement is required for every manuscript submitted in order to provide appropriate credit to all authors and assign responsibility and accountability for a published work. This section should state who has contributed what to the planning, conduct, and reporting of the work described in the article. Each author's name must be written only by the first letter of the given name and surname, without full stop, but separated by commas (e.g. AA, performed the laboratory assessment; JS and SH, collected samples; AO, ME, and OS, analyzed the data).
  
- ***Corresponding author:*** A corresponding author is the person who takes primary responsibility for all communications with IBJ during the manuscript submission, peer review, and the publication process, while ensuring adherence to all administrative requirements. The corresponding author should also be available throughout the process to respond to any and all editorial queries, as well as after publication to respond to any critiques and/or comments.

### ***Add, remove, change of author’s name***

- Any changes in the list of authors are not accepted after acceptance. For all submissions to *Iranian Biomedical Journal* (IBJ), request of authorship change during review process and before acceptance should be made to the Editorial Office of IBJ. ([see the form authorship change agreement](#))

### ***Publication ethics***

1. All editorial members, reviewers, and authors must conform to the rules defined by Committee on Publication (COPE).
2. IBJ confronts any ethical misbehavior, including duplications, plagiarism, fraudulent data, or any other kinds of fraud, in which case the [COPE flowcharts](#) and guidelines will be followed.
3. IBJ follows the guidelines stated in the Recommendations for the conduct, reporting, editing, and publication of scholarly work in Medical Journals issued by [the International Committee of Medical Journal Editors \(ICMJE\)](#).
4. The corresponding author is considered as the main person, responsible for the article, who will be approached upon any related mischief.
5. Major changes in the article after acceptance are not allowed.
6. Manuscripts submitted to IBJ must comply with the following policies to ensure ethical publication of academic work.

- **Republishing**  
IBJ does not accept manuscripts that have already been published elsewhere, even in languages other than English.
- **Plagiarism**  
All submissions to IBJ are screened for textual overlap by the software CrossCheck, powered by iThenticate, at two levels: prior to the review process and also issuance of the acceptance letter. Plagiarized articles will be immediately rejected.
- **Duplication**  
Manuscripts submitted to IBJ must not have been formerly published or be under consideration for publication elsewhere, in whole or in part.
- **Fabrication and falsification**  
Neither the fabrication of data or images (i.e. fake or made up data) and falsification of data or images (i.e. the international misrepresentation or deceptive manipulation of data) are allowed in IBJ. In case of fabrication and falsification, [COPE's guidelines](#) are followed.
- **Image manipulation**
  1. Any specific feature within an image (e.g. enhanced, obscured, moved, recycled, removed, or added) is not allowed.
  2. Adjustments of brightness, contrast, or color balance are acceptable, only if they are applied to every pixel in the image and as long as they do not obscure, eliminate, or misrepresent any information present in the original source, including the background ([COPE flowchart about Image Manipulation](#)).

### **Retraction policy**

As a member of the [COPE](#), IBJ uses [COPE flowchart for retraction of a published article](#) to determine whether a published article should be retracted.

### **REVIEW PROCESS**

When a manuscript is submitted to the Journal, it is given a reference code for future communication with the corresponding author. All manuscripts are read by the editors and at least two qualified external reviewers to ensure both accuracy and relevance. Reviewers are asked to be objective in their evaluations and to judge primarily the novelty and soundness of the information presented. Authors are encouraged to suggest 3 to 5 appropriate reviewers, although the actual selection of referees will be made by the EIC. Authors may also indicate specific individuals, whom they would like to be excluded as reviewers. In the review of any manuscript, the identity of the reviewers and authors and also information contained in the manuscript are considered confidential. Online tracking of the review process is possible through the corresponding author's private page in the IBJ website.

### **Reviewers**

1. Reviewers should not disclose any information obtained during the peer-review process, or use them for any purposes.
2. Reviewers should review objectively, devoid of any biases, or personal perspectives towards the authors.
3. Reviewers should express their views clearly and provide constructive comments for both authors and the editors.
4. Reviewers should point out any critically relevant published work that has not been cited by the authors.
5. Reviewers should notify the Editor-in-Chief (EIC) of any substantial similarity or overlap between the under-review manuscript and any other published paper.
6. Reviewers must not directly contact the authors, without prior permission of the EIC.

## **Editor-in-Chief**

1. EIC is accountable for the scientific integrity of papers published in IBJ.
2. EIC performs an initial review of all submitted manuscripts prior to peer review.
3. EIC makes decisions on the overall academic merit of the manuscript based on the priority of publication in IBJ, both before and after peer review.
4. EIC puts suspends all manuscripts, suspected of duplication, plagiarism, or image manipulation until further investigations.

## **Associate Editor**

Associate Editor has an advisory role for the EIC and takes on any and all tasks assigned by the EIC.

## **Preprint**

IBJ does NOT accept manuscripts posted to a preprint server. Furthermore, authors are not allowed to submit their manuscript to any related preprint server during the publication process.

## **REVISION**

Papers may be returned to the authors for modification of the scientific content and/or for shortening and language corrections. The revised version of the manuscript and a point-to-point response to the reviewers' comments, must be submitted to the Editor. The editor's suggestion regarding resubmission of the revised version of the manuscript, does not imply that it will be ultimately accepted. If the revision is not received within the allotted time, it will be regarded as having been withdrawn and any further submissions will be treated as new ones, unless otherwise agreed upon. Authors who resubmit a paper that has been previously rejected must provide the original manuscript and a letter explaining in detail how the paper has been modified.

## **PROOFS**

Proofs will be sent to the corresponding author to be checked for typographical errors and other essential yet minor changes. Proofs must be returned to the journal within one week of receipt.

## **Page charges**

IBJ does not charge any publication fees (such as membership, submission, article processing, etc) and provides free access to all its publications.

## **SUBMISSION PROCEDURE**

All submissions to IBJ should be conducted via the online submission platform, which provides an easy tracking access for both the authors and the reviewers. The complete manuscript, including Figures and Tables, should be sent together with the following items:

1. A cover letter, directed to the EIC, describing the novelty and significance of the submitted manuscript
2. Completed forms of "[Submission](#)" and "[Copyright form](#)"

For more information, please contact [iranianbiomedicalj@gmail.com](mailto:iranianbiomedicalj@gmail.com)